Want to read (8)
A comprehensive set of sequence analysis programs for the VAX
Devereux J, Haeberli P, Smithies O.
Nucleic Acids Res · 1984
mTOR Signaling in Growth, Metabolism, and Disease
Saxton RA, Sabatini DM.
Cell · 2017
Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9
Doench JG, Fusi N, Sullender M, Hegde M, Vaimberg EW, Donovan KF, Smith I, Tothova Z, Wilen C, Orchard R, Virgin HW, Listgarten J, Root DE.
Nat Biotechnol · 2016
Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage
Gaudelli NM, Komor AC, Rees HA, Packer MS, Badran AH, Bryson DI, Liu DR.
Nature · 2017
Inferring tumour purity and stromal and immune cell admixture from expression data
Yoshihara K, Shahmoradgoli M, Martínez E, Vegesna R, Kim H, Torres-Garcia W, Treviño V, Shen H, Laird PW, Levine DA, Carter SL, Getz G, Stemke-Hale K, Mills GB, Verhaak RG.
Nat Commun · 2013
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols MC, Cortinovis DL, Leach J, Polikoff J, Barrios C, Kabbinavar F, Frontera OA, De Marinis F, Turna H, Lee JS, Ballinger M, Kowanetz M, He P, Chen DS, Sandler A, Gandara DR, OAK Study Group.
Lancet · 2017
DNA targeting specificity of RNA-guided Cas9 nucleases
Hsu PD, Scott DA, Weinstein JA, Ran FA, Konermann S, Agarwala V, Li Y, Fine EJ, Wu X, Shalem O, Cradick TJ, Marraffini LA, Bao G, Zhang F.
Nat Biotechnol · 2013
Genetic basis for clinical response to CTLA-4 blockade in melanoma
Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, Walsh LA, Postow MA, Wong P, Ho TS, Hollmann TJ, Bruggeman C, Kannan K, Li Y, Elipenahli C, Liu C, Harbison CT, Wang L, Ribas A, Wolchok JD, Chan TA.
N Engl J Med · 2014